Editorial
Gene expression signatures in circulating tumor cells correlate with response to therapy in metastatic breast cancer
Abstract
Breast cancer is the most common cancer among women worldwide (1). Despite the development of new therapeutic strategies, metastatic breast cancer (MBC) remains an incurable disease characterized by a high clinical variability, partly linked to the molecular heterogeneity of both the primary tumor and its metastases (2).
